Hyperfractionated radiotherapy alone for clinical stage I nonsmall cell lung cancer

Purpose: Among patients with Stage I nonsmall cell lung cancer (NSCLC), those treated with conventional radiotherapy show poorer prognosis than those treated by surgery, To improve the prognosis of such patients, we have used hyperfractionated radiation therapy. Methods and Materials: Between 1988 and 1993, 49 patients were treated with hyperfractionated radiotherapy with 1.2 Gy twice daily to a total dose of 69.6 Gy, All patients were technically operable, but 29 had medical problems and 20 refused surgery, The median age and Karnofsky Performance Status was 63 years and 90, respectively, No patient received chemotherapy or immunotherapy, Prophylactic mediastinal irradiation was not given. Results: The median survival time was 33 months, and the 5-year survival rate was 30%, The rate at 5 years for freedom from each of relapse, local recurrence, mediastinal lymphnode metastasis, and distant metastasis was 41%, 55%, 89%, and 75%, respectively, Univariate analysis revealed that higher Karnofsky Performance Status score, absence of weight loss before treatment, and T1 stage were associated with better survival, although the T stage became insignificant on multivariate analysis, There were two Grade 3 acute toxicities and three Grade 3 late toxicities, but there was no Grade 4-5 toxicity, Conclusion: The results of this study compare favorably with those of most previous studies employing conventional fractionation, Further studies on hyperfractionation seem to be warranted for Stage I NSCLC. (C) 1997 Elsevier Science Inc.